Industry Trends | Published:

Functional antigenics

Nature Biotechnologyvolume 16pages305307 (1998) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Pharmaceutical Research Manufacturer's Association (PhRMA), 1997.

  2. 2

    Persidis, A. 1997. Nature Biotechnol. 15:1409–1411.

  3. 3

    Such antigens are mostly peptides, but they can also be glycopeptides, lipopeptides, or other types of nonpeptide molecule.

  4. 4

    Vose, B.M. and Bonnard, G.D. 1982. Nature 296:359.

  5. 5

    Murphy, G. et al. 1996. Prostate 29:371–380.

  6. 6

    Kawakami, Y. et al. 1995. J. Immunol. 154:3961–3968.

  7. 7

    Mayordomo, J.I. et al. 1995. Nat. Meet. 1:1297–1302.

  8. 8

    Vajda, S. and DeLisi, C. 1990. Biopolymers 29:1755.

  9. 9

    Skipper, J.C.A. et al. 1996. J. Exp. Med. 183:527–534.

  10. 10

    Meadows L. et al. 1997. Immunity 6:273–281.

  11. 11

    van der Bruggen, P. et al. 1991. Science 254:1643–1647.

  12. 12

    Henderson, R.A. et al. 1993. Proc. Natl. Acad. Sci. USA 90:10275–10279.

  13. 13

    Melief, C. et al. 1988. Ann. NY Acad. Sci. 532:280–291.

  14. 14

    McCormack, A.L. et al. 1997. Anal. Chem. 69:767–776.

  15. 15

    Evers, P. 1996. Immunoheraphy:Current status and markets. Financial Times Management Reports.

Download references

Author information

Affiliations

  1. vice president for business development at Argonex Inc., 2044 India Road, Suite 202, Charlottesvilk, VA, 22901

    • Aris Persidis

Authors

  1. Search for Aris Persidis in:

About this article

Publication history

Issue Date

DOI

https://doi.org/10.1038/nbt0398-305

Further reading